7th WBMT WORKSHOP

Commemorating Completion of 1200 Transplants at AFBMTC/NIBMT

Feb 2022

What are you waiting for?

Join this historical event.

Days
Hours
Minutes
Seconds

Welcome

Dear friends and colleagues,

On behalf of the Organizing Committee of ASH Live Review Pakistan, we welcome you to this historical event. This is the first American Society of Hematology (ASH) Licensed event in this part of the world. This scientific programme will offer a selection of studies describing latest advances in hematology and cutting-edge educational sessions with world experts. The program will provide a unique opportunity to share local data , real world experiences and challenges of developing countries. The event is organized by Armed Forces Bone Marrow Transplant Centre  National Institute of Blood and Marrow Transplant (AFBMTC /NIBMT), located in Rawalpindi, Pakistan. Established in 2001, AFBMTC/NIBMT is the only dedicated transplant centre of the country with capability of performing more than 150 allogeneic transplants year. AFBMTC/NIBMT is also the only centre of Pakistan to have a cellular therapy programme and an in house mesenchymal stem cell culture facility since 2015. This website will also provide you a chance to virtually explore Pakistan, one of the Forbes preferred tourist destination in 2020 and the land of nature and adventure. We are delighted to welcome our friends and participants from all over the world to the ASH Live Review Pakistan: Selected Highlights from the 2020 ASH Annual Meeting. We hope that this event will increase knowledge, skill, networking with new friends and colleagues and, last but not the least, to enjoy the Pakistani culture.

 

General Chairperson

Prof Dr Qamar Un Nisa Chaudhry
Professor of Clinical Haematology & BMT Physician
AFBMTC/NIBMT, Rawalpindi - PK

Programme Chairperson

Khurram Tariq, MD FACP
Chair, Dept of Hematology and medical Oncology
Seby B. Jones Cancer Center
Hematologist and medical oncologist
Boone, NC USA

Co-Chairperson

Prof Dr Parvez Ahmed
Professor, Director Bone Marrow Transplant
Quaid-e-Azam International Hospital,
Islamabad - PK

Co-Chairperson

Dr Syed Kamran Mahmood
Consultant Medical Specialist & BMT Physician
AFBMTC/NIBMT, Rawalpindi - PK

Secretary

Dr Raheel Iftikhar
Consultant Clinical Hematologist & BMT Physician
AFBMTC/NIBMT, Rawalpindi -

HOSTED BY

AFBMTC/NIBMT

Rawalpindi – Pakistan

\\ Speakers //

\\ Panelists //

\\ Moderators //

Azhar Shafi

Consultant Haematologist

Jahanzaib ur Rahman

Consultant Hematologist

Ghassan Umair Shamshad

Consultant Haematologist

Mehreen Ali Khan

Consultant Haematologist

Muhammad Farhan

Consultant Haematologist

Natasha Ali

Consultant Haematologist

Nighat Shahbaz

Consultant Haematologist

Raheel Iftikhar

Classified Medical Specialist & BMT Physician

Usman Ahmed

Consultant Hematologist

Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.

Abstracts
Registrations
Sessions
Speakers/Panelists

\\ PROGRAM //

Day 1 - Friday, 30 july 2021

EST: 0800-0930 PST: 1700-1830

Session – I

Hematological Malignancies

Topic

Acute Myeloid Leukemia & MDS

Moderator

Raheel Iftikhar

AFBMTC/NIBMT
Rawalpindi – PK

Speaker & Panelist

Irum Khan

University of Illinois Hospital

Chicago – IL

Salman Fazal

West Penn Hospital

Pittsburgh – PA

Panelist 

Tahir Sultan Shamsi

National Institute of Blood Diseases & BMT

Karachi – PK

Syed Ali Abutalib

CTCA Outpatient Care Center

Chicago, IL – USA

EST: 0930-1025 PST: 1830-1925

Session – II

Benign Hematology

Topic

Coagulation and Thrombosis

Moderator

Ghassan Umair Shamshad

AFBMTC/NIBMT
Rawalpindi – PK

Speaker & Panelist

Vahid Afshar Kharghan

University of Texas MD Anderson Cancer Centre
Texas- USA

Panelist 

Lara Roberts

King’s College Hospital – NHS Foundation Trust

London – UK

Nadir Ali

Kulsum International Hospital

Islamabad – PK

Tahira Zafar

Hemophilia Patients Welfare Society
Rawalpindi – PK

Anila Rashid

The Aga Khan University Hospital

Karachi – PK

EST: 1025-1130 PST: 1925-2030

Session – III

Hematological Malignancies

Topic

Acute Lymphoblastic Leukemia

Moderator

Nighat Shahbaz

AFBMTC/NIBMT
Rawalpindi – PK

Speaker & Panelist

Shabeeha Rana

American Hospital

Dubai – UAE

Panelist 

Syed Ali Abutalib

CTCA Outpatient Care Center

Chicago, IL – USA

Zahra Fadoo

The Aga Khan University

Karachi – PK

Shahzad Nasir Raja

Quaid-e-Azam International

Islamabad – PK

Day 2 - saturday, 31 july 2021

EST: 0800-0900 PST: 1700-1800

Session – IV

Hematological Malignancies

Topic

Lymphoma

Moderator

Usman Ahmad

SKMCH & RC
Lahore – PK

Speaker & Panelist

Tanya Siddiqi

City of Hope National Medical Center

Duarte, CA – USA

M Salman Faisal (Speaker only)

The Ohio State University

Columbus, OH – USA

Panelist 

Farrukh T. Awan

UT Southwestern Medical Center

Dallas, TX – USA

Vasia Ahmed

Chicago Ridge, IL

Kamran Rashid

Rashid Nursing Home & Cancer Center

Rawalpindi – PK

EST: 0900-1030 PST: 1800-1930

Session – V

Hematological Malignancies

Topic

Lymphoma & CAR-T

Moderator

Azhar Shafi

Shifa International Hospital
Islamabad – PK

Speaker & Panelist

Sairah Ahmed

MD Anderson Cancer Center

Houston, TX – USA

Jasmine M. Zain

Toni Stephenson lymphoma centre at city of hope, Duarte, CA USA

Panelist 

Abdullah M. Khan

The Ohio State University

Columbus – USA

Syed Waqas Imam Bokhari

SKMCH & RC

Lahore – PK

EST: 1030-1130 PST: 1930-2030

Session – VI

Hematological Malignancies

Topic

Myeloproliferative Neoplasms

Moderator

Mehreen Ali Khan

AFBMTC/NIBMT
Rawalpindi – PK

Speaker & Panelist

Naseema Gangat

Mayo Foundation for Medical Education & Research

Rochester, FL – USA

Panelist 

Haris Ali

City of Hope National Medical Center

Duarte, CA – USA

Irum Khan

University of Illinois Hospital

Chicago – IL

M Usman Shaikh

The Aga Khan University Hospital

Karachi – PK

Day 3 - sunday, 01 august 2021

EST: 0800-0840 PST: 1700-1740

Session – VII

Benign Hematology

Topic

Bone Marrow Failure Syndromes

Moderator

Raheel Iftikhar

AFBMTC/NIBMT
Rawalpindi – PK

Speaker & Panelist

Qamar Un Nisa Ch.

AFBMTC/NIBMT

Rawalpindi – PK

Panelist 

Parvez Ahmed

Quaid-e-Azam International Hospital

Islamabad – PK

Salman Naseem Adil

The Aga Khan University Hospital

Karachi – PK

Syed Osman Ahmed

KFSHRC · Oncology Center

Riyadh – KSA

EST: 0840-0940 PST: 1740-1840

Session – VIII

Multiple Myeloma

Topic

Multiple Myeloma & Amyloidosis

Moderator

Jahanzeb Ur Rahman

CMH

Bahawalpur

Speaker

Hamza Hashmi

Hollings Cancer Center – MUSC Health

Charleston, SC – USA

Panelist 

Saad Usmani

UNC-CH School of Medicine

Chapel Hill, NC – USA

Zeba Aziz

Hameed Latif Hospital

Lahore – PK

Maria Chaudhry

Ohio State University Wexner Medical Center Columbus Ohio, USA

Syed Abbas Ali

The Johns Hopkins University School of Medicine

Baltimore, MD – USA

M Ayaz Y. Mir

Shifa International Hospital

Islamabad – PK

EST: 0940-1030 PST: 1840-1930

Session – IX

Benign Hematology

Topic

Hemoglobinopathies

Moderator

Muhammad Farhan

Gambat Institute of Medical Scienecies Gambat – PK

Speaker & Panelist

Damiano Rondelli

University of Illinois Hospital

Chicago, IL – USA

Panelist 

Hatoon Ezzat

St. Paul’s Hospital

Vancouver, Canada

Tariq Mahmood Satti

Shifa International Hospital

Islamabad – PK

Tariq Ghafoor

AFBMTC/NIBMT

Rawalpindi – PK

EST: 1030-1130 PST: 1930-2030

Session – X

Transplantation & CAR-T Cell

Topic

Complications of HSCT

Moderator

Natasha Ali

The Aga Khan University Hospital Karachi – PK

Speaker & Panelist

Shahrukh K. Hashmi

Mayo Foundation for Medical Education and Research

Rochester, Minnesota – USA

Panelist 

Farrukh T. Awan

UT Southwestern Medical Center

Dallas, TX – USA

Syed Kamran Mahmood

AFBMTC/NIBMT

Rawalpindi – PK

Munira Moosajee

The Aga Khan Univeristy Hospital

Karachi – PK

\\ Abstracts //

  • Day 1
  • Irum Khan
    Irum Khan 1700-1730

    1. Abstract # 333. Efficacy and safety of Venetoclax in combination with Gilteritinib for R/R FLT3-mutated AML in the expansion cohort of a phase 1b. Daver et al.
    2. Abstract # 693: Outcomes of TP53 mutant AML with Venetoclax and Decitabine. Kim et al.

  • Salman Fazal
    Salman Fazal 1730-1800

    1. Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Bas eline Erythropoietin Levels
    2. Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

  • Vahid Afshar Kharghan
    Vahid Afshar Kharghan 1830-1900

    1. Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial
    2. A Retrospective Cohort Study Evaluating the Safety and Efficacy of Peri-Partum Tranexamic Acid for Women with Inherited Bleeding Disorders

  • Shabeeha Rana
    Shabeeha Rana 1925-1955

    1. Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial
    2. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

  • Day 2
  • Mohammad Salman Faisal
    Mohammad Salman Faisal 1700-1705

    Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

  • Tanya Siddiqi
    Tanya Siddiqi 1705-1735

    1. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
    2. Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

  • Sairah Ahmed
    Sairah Ahmed 1800-1830

    1. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
    2. Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

  • Jasmine Zain
    Jasmine Zain 1830-1900

    1. Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-
    2 and/or BCL-6 Gene Rearrangements or Increase Copy Number 2.Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

  • Naseema Gangat
    Naseema Gangat 1930-2000

    1. Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms
    2. abstract 481 long term use of ropeginterferon alpha 2b in PV 5 year results from a randomized controlled study

  • Day 3
  • Qamar un nisa Chaudhry
    Qamar un nisa Chaudhry 1700-1720

    1.A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia: (FluCAB-Prime)
    2. Disease Progression and Outcomes in Patients with Telomere Biology Disorders

  • Hamza Hashmi
    Hamza Hashmi 1740-1810

    1. Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
    2. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial
    3. Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
    4. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

  • Damiano Rondelli
    Damiano Rondelli 1840-1910

    1. Safety and efficacy of CTX001 in patients with transfusion-dependent beta-thalassemia and sickle cell disease: early results from the Climb THAL-111 and Climb SCD-121 studies of autologous CRISPR-CAS9-modified CD34+ hematopoietic stem and progenitor cells

  • Shahrukh K Hashmi
    Shahrukh K Hashmi 1930-2000

    1. Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213
    2. REACH 3 trial: Ruxolitinib for cGVHD 3. Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Contact Us

If you have any questions about the event or the team of lecturers, please send us a message and we will reply shortly.

For more information and details, contact our customer service

Conference Secretariat:
AFBMTC/NIBMT, CMH Medical Complex, Rawalpindi – Pakistan
Tel: +92 51 9270076 Ext 228, Cell & WhatsApp: +92 322 5181302, +92 310 2500292
Email: WBMT2022Pakistan@gmail.com